DIAGNOS Inc. (ADK.V)
- Simply Wall St.
DIAGNOS First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
DIAGNOS ( CVE:ADK ) First Quarter 2025 Results Key Financial Results Revenue: CA$36.7k (down 15% from 1Q 2024). Net...
- GlobeNewswire
DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
BROSSARD, Quebec, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces that the 2024 annual general and special meeting of shareholders (the “Meeting”) will be held on September 25th, 2024, at 10 a.m. Purposes of the Meeting To receive the annual report of management, the audited consolidated fin
- GlobeNewswire
DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada
BROSSARD, Quebec, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today that its quality management system fully complies with ISO 13485 standard and applicable regulatory requirements for medical devices. As part of the requirements for the commercialization of our flagship product CARA, DI
